{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:22:33Z","timestamp":1783689753297,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.autrev.2020.102681","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T22:54:07Z","timestamp":1603320847000},"page":"102681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Guillain Barr\u00e9 syndrome and COVID-19: Possible role of the cytokine storm"],"prefix":"10.1016","volume":"19","author":[{"given":"Faraz S.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Eldeeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Blackmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaeem A.","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10224","key":"10.1016\/j.autrev.2020.102681_bb0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102681_bb0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41422-020-0327-4","article-title":"COVID-19: towards understanding of pathogenesis","volume":"30","author":"Cao","year":"2020","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.autrev.2020.102681_bb0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2020.102681_bb0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10072-020-04449-8","article-title":"Early Guillain-Barr\u00e9 syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital","volume":"41","author":"Ottaviani","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2020.102681_bb0025","doi-asserted-by":"crossref","first-page":"577294","DOI":"10.1016\/j.jneuroim.2020.577294","article-title":"Guillain-Barr\u00e9 syndrome in a patient infected with SARS-CoV-2, a case report","volume":"346","author":"Farzi","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2020.102681_bb0030","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/NXI.0000000000000785","article-title":"Guillain-Barr\u00e9 syndrome related to SARS-CoV-2 infection","volume":"7","author":"Bigaut","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"26","key":"10.1016\/j.autrev.2020.102681_bb0035","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1056\/NEJMc2009191","article-title":"Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2","volume":"382","author":"Toscano","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2020.102681_bb0040","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1474-4422(13)70215-1","article-title":"Axonal Guillain-Barr\u00e9 syndrome: concepts and controversies","volume":"12","author":"Kuwabara","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2020.102681_bb0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/jnnp.66.3.277","article-title":"Infections and the Guillain-Barr\u00e9 syndrome","volume":"66","author":"Hartung","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.autrev.2020.102681_bb0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","article-title":"Guillain-Barr\u00e9 syndrome associated with preceding hepatitis E virus infection","volume":"82","author":"van Den Berg","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2020.102681_bb0055","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/cid\/cit512","article-title":"Hepatitis E and Guillain-Barr\u00e9 syndrome","volume":"57","author":"Geurtsvankessel","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.autrev.2020.102681_bb0060","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaneurol.2018.1058","article-title":"Clinical features of Guillain-Barr\u00e9 syndrome with vs without zika virus infection, Puerto Rico, 2016","volume":"75","author":"Dirlikov","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2020.102681_bb0065","doi-asserted-by":"crossref","first-page":"116576","DOI":"10.1016\/j.jns.2019.116576","article-title":"Antiganglioside antibodies in neurological diseases","volume":"408","author":"Wanleenuwat","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2020.102681_bb0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jnnp.66.4.513","article-title":"Antiganglioside antibody in patients with Guillain-Barr\u00e9 syndrome who show bulbar palsy as an initial symptom","volume":"66","author":"Koga","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2020.102681_bb0075","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jnnp-2016-314310","article-title":"Zika virus infection and Guillain-Barr\u00e9 syndrome: a review focused on clinical and electrophysiological subtypes","volume":"88","author":"Uncini","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"10.1016\/j.autrev.2020.102681_bb0080","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.autrev.2020.102567","article-title":"Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions","volume":"19","author":"Jamilloux","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2020.102681_bb0085","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"issue":"5","key":"10.1016\/j.autrev.2020.102681_bb0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cytogfr.2013.05.005","article-title":"Th1\/Th2\/Th17\/Treg cytokines in Guillain-Barr\u00e9 syndrome and experimental autoimmune neuritis","volume":"24","author":"Zhang","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2020.102681_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0165-5728(98)00053-8","article-title":"Elevated serum levels of IFN-\u03b3, IL-4 and TNF-\u03b1\/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage","volume":"87","author":"Hohnoki","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2020.102681_bb0100","doi-asserted-by":"crossref","first-page":"260473","DOI":"10.1155\/2012\/260473","article-title":"IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barr\u00e9 syndrome","volume":"2012","author":"Li","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2020.102681_bb0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-2094-11-63","article-title":"Interleukin-17 impedes schwann cell-mediated myelination","volume":"11","author":"Stettner","year":"2014","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2020.102681_bb0110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12026-014-8580-6","article-title":"Intravenous immunoglobulin exerts reciprocal regulation of Th1\/Th17 cells and regulatory T cells in Guillain-Barr\u00e9 syndrome patients","volume":"60","author":"Maddur","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2020.102681_bb0115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbi.2020.03.031","article-title":"Nervous system involvement after infection with COVID-19 and other coronaviruses","volume":"87","author":"Wu","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.autrev.2020.102681_bb0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"issue":"2","key":"10.1016\/j.autrev.2020.102681_bb0125","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/14787210.3.2.251","article-title":"Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome","volume":"3","author":"Chihrin","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.autrev.2020.102681_bb0130","first-page":"121","article-title":"Severe acute respiratory syndrome: clinical and laboratory manifestations","volume":"25","author":"Lam","year":"2004","journal-title":"Clin Biochem Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220302585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:22Z","timestamp":1761600022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220302585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1568997220302585"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102681","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guillain Barr\u00e9 syndrome and COVID-19: Possible role of the cytokine storm","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102681"}}